Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.

ABSTRACT: Importance:Comparative real-world effectiveness studies of initial disease-modifying treatment (DMT) choices for relapsing-remitting multiple sclerosis (RRMS) that include rituximab are lacking. Objective:To assess the effectiveness and drug discontinuation rates of rituximab among patients with newly diagnosed RRMS compared with injectable DMTs, dimethyl fumarate, fingolimod, or natalizumab. Design, Setting, and Patients:This retrospective cohort study used prospectively collected data to examine specialized care of 2 Swedish county-based community samples of patients with RRMS. Patients with RRMS who received diagnoses from January 1, 2012, to October 31, 2015, who resided in Stockholm or Västerbotten Counties were identified from a Swedish multiple sclerosis registry. Main Outcomes and

SUBMITTER: Granqvist M 

PROVIDER: S-EPMC5885857 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature